Psychedelic Drugs Offering New Hope for Treatment of Debilitating Disorders
October 15, 2020 08:30 ET
|
Cybin Corp.
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire — Cybin Corp. today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ brands in the...
Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder
September 14, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Rapid, durable, and statistically significant improvement demonstrated in patient-reported depressive symptoms, as measured by the QIDS-SR-16 total score compared to placebo (p=0.001) Clinical...
Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress
September 10, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
July 30, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting
May 29, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 08, 2020 07:00 ET
|
Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications
March 30, 2020 06:00 ET
|
Axsome Therapeutics, Inc.
Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary...
Solace Behavioral Health Clinic Hosts Grand Opening to Introduce Newly Offered FDA-Cleared Helmet to Treat Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)
February 20, 2020 09:00 ET
|
Solace Behavioral Health
TAMPA, Fla., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Solace Behavioral Health, a mental health clinic offering advanced treatments for mental health disorders, announced today that it will host an grand...
West Yavapai Guidance Clinic Hosts Open House to Introduce Newly Offered FDA-Cleared Helmet to Treat Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)
February 06, 2020 09:39 ET
|
West Yavapai Guidance Clinic
PRESCOTT VALLEY, Ariz., Feb. 06, 2020 (GLOBE NEWSWIRE) -- West Yavapai Guidance Clinic, a non-profit mental health facility offering advanced treatments for behavioral and mental health disorders,...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in GEMINI Phase 3 Trial in Major Depressive Disorder
December 16, 2019 06:00 ET
|
Axsome Therapeutics, Inc.
Demonstrated rapid, durable, and statistically significant improvement in depressive symptoms as measured by MADRS total score compared to placebo (p=0.002 on primary endpoint) Statistically...